Show simple item record

dc.contributor.authorSingh, Shivani
dc.contributor.authorWeiss, Anne
dc.contributor.authorGoodman, James
dc.contributor.authorFisk, Marie
dc.contributor.authorKulkarni, Spoorthy
dc.contributor.authorLu, Ing
dc.contributor.authorGray, Joanna
dc.contributor.authorSmith, Rona
dc.contributor.authorSommer, Morten
dc.contributor.authorCheriyan, Joseph
dc.date.accessioned2022-04-12T08:00:32Z
dc.date.available2022-04-12T08:00:32Z
dc.date.issued2022-07
dc.date.submitted2021-09-22
dc.identifier.issn0007-1188
dc.identifier.otherbph15843
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/336018
dc.descriptionFunder: Evelo Biosciences
dc.descriptionFunder: AstraZeneca; Id: http://dx.doi.org/10.13039/100004325
dc.descriptionFunder: UNION Therapeutics, Denmark
dc.descriptionFunder: Kidney Research UK; Id: http://dx.doi.org/10.13039/501100000291
dc.descriptionFunder: Addenbrooke's Charitable Trust, Cambridge University Hospitals; Id: http://dx.doi.org/10.13039/501100002927
dc.descriptionFunder: LifeArc; Id: http://dx.doi.org/10.13039/100012357
dc.description.abstractVaccines have reduced the transmission and severity of COVID-19 but there remains a paucity of efficacious treatment for drug resistant strains and more susceptible individuals, particularly those who mount a sub-optimal vaccine response, either due to underlying health conditions or concomitant therapies. Repurposing existing drugs is a timely, safe and scientifically robust method for treating pandemics such as COVID-19. Here, we review the pharmacology and scientific rationale for repurposing niclosamide, an anti-helminth already in human use as a treatment for COVID-19. In addition to potent antiviral activity, niclosamide has shown pleiotropic anti-inflammatory, antibacterial, bronchodilatory and anticancer effects in numerous pre-clinical and early clinical studies. The advantages and rationale for nebulised and intranasal formulations of niclosamide, which target the site of primary infection in COVID-19, are reviewed. Finally, we provide an overview of ongoing clinical trials investigating niclosamide as a promising candidate against SARS-CoV-2.
dc.description.sponsorshipThe PROTECT-V trial is overseen by the NIHR Covid-19 Understanding and Elimination-Trials Implementation Panel (CUE-TIP). PROTECT-V is funded by LifeArc, Addenbrooke’s Charitable Trust and Kidney Research UK with financial contributions from Union Therapeutics for the niclosamide arm. The TACTIC-E trial is funded by UNION Therapeutics, Denmark as well as AstraZeneca and Evelo Biosciences with significant financial support from the NIHR Cambridge BRC. RS and JC acknowledge funding support from the Cambridge NIHR BRC. MS is a shareholder of UNION Therapeutics and AW benefits from an employee incentive scheme. AW and MS also acknowledge support from Innovation Fund Denmark under grant number 0153-00209 and The Novo Nordisk Foundation under NFF grant number NNF20CC0035580, respectively.
dc.languageen
dc.publisherWiley
dc.subjectREVIEW ARTICLE
dc.subjectREVIEW ARTICLES
dc.subjectclinical trials
dc.subjectCOVID‐19
dc.subjectniclosamide
dc.subjectrepurposing
dc.titleNiclosamide ‐ a promising treatment for COVID‐19
dc.typeArticle
dc.date.updated2022-04-12T08:00:31Z
prism.publicationNameBritish Journal of Pharmacology
dc.identifier.doi10.17863/CAM.83449
dcterms.dateAccepted2022-02-23
rioxxterms.versionofrecord10.1111/bph.15843
rioxxterms.versionAO
rioxxterms.versionVoR
rioxxterms.licenseref.urihttp://creativecommons.org/licenses/by/4.0/
dc.contributor.orcidGoodman, James [0000-0002-1659-7644]
dc.contributor.orcidFisk, Marie [0000-0002-1292-7642]
dc.contributor.orcidSmith, Rona [0000-0002-7438-5156]
dc.contributor.orcidCheriyan, Joseph [0000-0001-6921-1592]
dc.identifier.eissn1476-5381
pubs.funder-project-idNational Institute for Health Research (IS-BRC-1215-20014)
cam.issuedOnline2022-03-29


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record